大小单双APP(正规好玩)官方网站

新闻资讯 News & Events

Press Release Events

2025

10-28

Juventas Ina-cel Injection: Six Studies to be Presented at the 2025 ASH Annual Meeting
2025

08-20

A New Chapter for Pediatric Leukemia Treatment: Juventas’ Inaticabtagene Autoleucel Injection for the Treatment of Children Acute Leukemia was Granted Breakthrough Therapy Designation
2025

06-23

Juventas’ Ina-cel Injection (YORWIDA®) Granted Breakthrough Therapy Designation by Saudi FDA, Accelerating Access for Middle Eastern Blood Cancer Patients
2025

04-24

Juventas Announces NMPA Clearance of Ina-cel for the Treatment of Lupus Nephritis (LN)
2025

04-16

Juventas Cell Therapy Partners with Beijing Tiantan Hospital to Advance CAR-T Therapies for Rare Neurological Disorders
2025

04-10

Juventas Announces NMPA Clearance for Global First-in-Class CAR-T Ina-cel for the Treatment of Autoimmune Hemolytic Anemia (AIHA)
2025

03-07

Delegation from ASEAN-China Center, ASEAN Ambassadors, and Chambers of Commerce Visits Juventas Cell Therapy Ltd.
2024

12-19

Juventas Announces the Launch of Inaticabtagene Autoleucel Injection for Marketing In Macao
2024

12-07

Long-term Efficacy and Safety Results of Ina-cel l in the Treatment of Adult Patients with r/r LBCL Published on Blood Advances
2024

11-07

2024 ASH | Juventas to Present Data and Two Early-stage Research Results of Ina-cel in Autoimmune Diseases, Adult and Pediatric Acute Lymphoblastic Leukemia
2024

11-05

The SFDA CEO Reviews the Manufacturing Technologies of Biological and Genetic Medicines in China
2024

10-11

Investigational New Drug Application Approved for Inaticabtagene Autoleucel Treating Autoimmune Diseases

Click to load more +

我们的目标 Focus on Cell Therapy, Lead a Healthy Future.